Kedaara Capital’s USD 200 million strategic investment in Tynor Orthotics

On August 25 2026, Kedaara Capital announced a USD 200 million strategic investment in Tynor Orthotics Private Limited, the Indian market’s #1 doctor‑recommended orthopaedic supports, mobility aids and rehabilitation solutions brand. Founded in 1993, Tynor now serves over 300,000 retail outlets and 8,000 hospitals across 60 countries, having impacted more than 100 million lives.

The company operates three state‑of‑the‑art manufacturing facilities spanning 6.5 lac sq ft (approximately 650,000 sq ft) that employ lean processes to produce global‑grade orthopaedic products at competitive prices. Kedaara Capital will collaborate closely with Tynor’s promoters—Dr. P.J. Singh and Mr. A.J. Singh—its professional management team, and long‑standing strategic partner Thuasne® to expand the brand’s reach within India, accelerate international market penetration, and further invest in advanced manufacturing capabilities.

In remarks, Dr. P.J. Singh and Mr. A.J. Singh expressed pride in welcoming Kedaara, citing the firm’s strong performance history and operational expertise as catalysts for an “unprecedented trajectory of growth.” Sunish Sharma, Founder and Managing Partner of Kedaara Capital, highlighted India’s medical‑devices sector as one of the fastest‑growing globally and described Tynor as a rare opportunity to partner with a clear category leader. Sumit Gupta and Nishant Naveen, Managing Director and Principal respectively, added that Tynor’s strong doctor equity, deep distribution network, R&D capabilities, and lean manufacturing foundation provide significant headroom for scaling into a global orthotics champion.

Thuasne® Group’s Chairman, Elizabeth Ducottet, noted a fifteen‑year partnership with Tynor and a shared ambition to make high‑quality orthopaedic solutions widely accessible. CEO Delphine Hanton said Kedaara’s entry opens a new chapter, combining Tynor’s entrepreneurial strengths with Kedaara’s scaling capabilities and Thuasne’s international orthopaedic expertise. Rochelle Dsouza of Lighthouse Funds, a long‑time partner of Tynor, praised the company’s commitment to product quality and its eight‑year collaboration with the fund.

o3 Capital acted as the exclusive financial advisor for the transaction. The press release also provides background on the investors: Kedaara Capital manages over $6 billion across sectors such as healthcare, financial services, consumer, and technology, and partners with global private‑equity firm Clayton, Dubilier & Rice. Thuasne is an international family‑owned healthcare group specializing in orthopaedics and medical compression, having partnered with Tynor since 2010.

Key facts

  • Investment amount: USD 200 million
  • Tynor founded: 1993
  • Retail footprint: >300,000 outlets
  • Hospital footprint: >8,000 hospitals
  • International presence: 60 countries
  • Lives impacted: >100 million
  • Manufacturing space: 6.5 lac sq ft across three facilities
  • Financial advisor: o3 Capital (exclusive)
  • Strategic partners: Thuasne® and Lighthouse Funds